nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.08.2009 | Original Paper

Medical history and risk of lymphoma: results of a European case–control study (EPILYMPH)

verfasst von: Nikolaus Becker, Joan Fortuny, Tomas Alvaro, Alexandra Nieters, Marc Maynadié, Lenka Foretova, Anthony Staines, Paul Brennan, Paolo Boffetta, Pier Luigi Cocco, Silvia de Sanjose

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 8/2009

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Lymphomas are a heterogeneous group of immune-cell malignancies. Immunology-related conditions are among the few factors for which consistent evidence exists relating them to lymphoma risk.

Materials and methods

We used the data from the European case–control study Epilymph on 2,362 lymphoma cases and 2,458 controls to investigate associations between a medical history of infectious and non-infectious diseases with overall and subentity-specific lymphoma risk.

Results

As key results, we observed an increased odds ratio (OR) for self-reported infections with hepatitis B virus (HBV, OR = 1.91, 95% CL = 1.24–2.94) and a null result for rheumatoid arthritis. Additionally, we found an increased OR for infectious mononucleosis (OR = 1.68, 95% CL = 1.14–2.48), an inverse association to frequency of sickness in childhood (OR = 0.68, 95% CL = 0.55–0.84), and—as casual finding—an increased OR with acetaminophen intake (OR = 2.29, 95% CL = 1.49–3.51).

Conclusion

Our results are consistent with the current knowledge about the association with mononucleosis as indicator of Epstein–Barr-virus infection, suggest serological study of the association to HBV infection and do not support the view of a positive association between rheumatoid arthritis and lymphoma risk.

Alexander DD, Mink PJ, Adamit H-O, Chang ET, Cole P, Mandel JS, Trichopoulos D (2007) The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer 120:1–39. doi:10.1002/ijc.22719 PubMedCrossRef

Anderson LA, Pfeiffer R, Warren JL, Landgren O, Gadalla S, Berndt SI, Ricker W, Parsons R, Wheeler W, Engels EA (2008) Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol Biomarkers Prev 17(11):3069–3075. doi:10.1158/1055-9965.EPI-08-0408 PubMedCrossRef

Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L (1998) Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case–control study. Br Med J 317:180–181

Baris D, Zahm SH (2000) Epidemiology of lymphomas. Curr Opin Oncol 12:383–394. doi:10.1097/00001622-200009000-00002 PubMedCrossRef

Becker N, Deeg E, Nieters A (2004) Population-based study of lymphomas in Germany: rationale, study design and first results. Leuk Res 28:713–724. doi:10.1016/j.leukres.2003.11.010 PubMedCrossRef

Becker N, Deeg E, Rüdiger T, Nieters A (2005) Medical history and risk for lymphoma: results of a population-based case–control study in Germany. Eur J Cancer 41:133–142. doi:10.1016/j.ejca.2004.08.028 PubMedCrossRef

Becker N, de Sanjosé S, Nieters A, Maynadié M, Foretova L, Cocco PL, Staines A, Alvaro T, Vornanen M, Brennan P, Boffetta P (2007) Birth order, allergies and lymphoma risk: results of the European collaborative research project Epilymph. Leuk Res 31:1365–1372. doi:10.1016/j.leukres.2007.02.019 PubMedCrossRef

Besson H, Brennan P, Becker N, Nieters A, de Sanjosé S, Font R, Maynadié M, Foretova L, Cocco PL, Staines A, Vornanen M, Boffetta P (2006) Tobacco smoking, alcohol drinking and non-Hodgkin lymphoma: a European multicenter case–control study (Epilymph). Int J Cancer 119:901–908. doi:10.1002/ijc.21913 PubMedCrossRef

Boffetta P, Armstrong B, Linet M, Kasten C, Cozen W, Hartge P (2007) Consortia in cancer epidemiology: lessons from the Interlymph. Cancer Epidemiol Biomarkers Prev 16:197–199. doi:10.1158/1055-9965.EPI-06-0786 PubMedCrossRef

Cartwright R, Brincker H, Carli PM, Clayden D, Coebergh JW, Jack A, McNally R, Morgan G, de Sanjose S, Tumino R, Vornanen M (1999) The rise in incidence of lymphomas in Europe 1985–1992. Eur J Cancer 35:627–633. doi:10.1016/S0959-8049(98)00401-8 PubMedCrossRef

Cocco P, Piras G, Monne M, Uras A, Gabbas A, Ennas MG, Palmas A, Murineddu M, Collu S, Melis M, Rais M, Todde P, Cabras MG, Angelucci E, Massarelli G, Nieters A (2008) Risk of malignant lymphoma following viral hepatitis infection. Int J Hematol 87:474–483. doi:10.1007/s12185-008-0086-3 PubMedCrossRef

Devesa SS, Fears T (1992) Non-Hodgkin’s lymphoma time trends: United States and International Data. Cancer Res 52:5432s–5440sPubMed

Ekström Smedby K, Hjalgrim H, Askling J, Chang ET, Gregersen H, Porwit-MacDonald A, Sundström C, Akerman M, Melbye M, Glimelius B, Adami H-O (2006) Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 98:51–60CrossRef

Ekström Smedby K, Vajdic CM, Falster M, Engels EA, Martinez-Maza O, Turner J, Hjalgrim H, Vineis P, Seniori Costantini A, Bracci PM, Holly EA, Willett E, Spinelli JJ, La Vecchia C, Zheng T, Becker N, De Sanjosé S, Chiu BC-H, Dal Maso L, Cocco P, Maynadié M, Foretova L, Staines A, Brennan P, Davis S, Severson R, Cerhan JR, Breen EC, Birmann B, Grulich AE, Cozen W (2008) Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 111:4029–4038. doi:10.1182/blood-2007-10-119974 PubMedCrossRef

Fortuny J, Benavente Y, Bosch R, García-Villanueva M, de Sevilla AF, de Sanjosé S (2005) Type 2 diabetes mellitus, its treatment and risk for lymphoma. Eur J Cancer 41:1782–1787. doi:10.1016/j.ejca.2005.04.032 PubMedCrossRef

Fortuny J, de Sanjosé S, Becker N, Maynadié M, Cocco PL, Staines A, Foretovea L, Vornanen M, Brennan P, Nieters A, Alvaro T, Boffetta P (2006) Statin use and risk of lymphoid neoplasms: results from the European case–control study EPILYMPH. Cancer Epidemiol Biomarkers Prev 15(5):921–925. doi:10.1158/1055-9965.EPI-05-0866 PubMedCrossRef

Gridley G, McLaughlin JK, Ekbom A, Klareskog L, Adami H-O, Hacker DG, Hoover R, Fraumeni JF Jr (1993) Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85:307–311. doi:10.1093/jnci/85.4.307 PubMedCrossRef

Holford TR, Zheng T, Mayne ST, McKay LA (1992) Time trends of non-Hodgkin’s lymphoma: are they real? what do they mean? Cancer Res 52:5443s–5446sPubMed

Howe HL, Wingo PA, Thun MJ, Ries LAG, Rosenberg HM, Feigal EG, Edwards BK (2001) Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst 93:824–842. doi:10.1093/jnci/93.11.824 PubMedCrossRef

Jaffé ESHN, Stein H, Vardiman JW (eds) (2001) Pathology and genetics of tumours of hematopoietic and lymphoid tissues. IARC Press, Lyon (France)

Kim LH, Bang Y-J, Park BJ, Yoo T, Kim CW, Kim T-Y, Heo DS, Lee H-S, Kim NK (2002) Hepatitis B virus infection and B-cell non-Hodgkin lymphoma in a hepatitis B endemic area: a case–control study. Jpn J Cancer Res 93:471–477PubMed

Kuniyoshi M, Nakamuta M, Sakai H, Enjoji M, Kinukawa N, Kotoh K, Fukutomi M, Yokota M, Nishi H, Iwamoto H, Uike N, Nishimura J, Inaba S, Maeda Y, Nawata H, Muta K (2001) Prevalence of hepatitis B or C virus infections in patients with non-Hodgkin’s lymphoma. J Gastroenterol Hepatol 16:215–219. doi:10.1046/j.1440-1746.2001.02406.x PubMedCrossRef

La Vecchia C, Negri E, Franceschi S, d’Avanzo B, Boyle P (2004) A case–control study of diabetes mellitus and cancer risk. Br J Cancer 70:950–953

Marcucci F, Mele A, Spada E, Candidi A, Bianco E, Pulsioni A, Chionne P, Madonna E, Cotichini R, Barbui A, de Renzo A, Dore F, Iannitto E, Liso V, Martino B, Montanaro M, Pagano L, Musto P, Rapicetta M (2006) High prevalence of hepatitis B virus infection in B-cell non-Hodgkin’s lymphoma. Haematologica 91:554–557PubMed

Martinez-Gamboa L, Brezinschek H-P, Burmester GR, Dörner T (2006) Immunopathologic role of B lymphocoytes in rheumatoid arthritis: rationale of B cell-directed therapy. Autoimmun Rev 5:437–442. doi:10.1016/j.autrev.2006.02.004 PubMedCrossRef

Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH (1996) Rheumatoid arthritis and cancer risk. Eur J Cancer 32A(10):1753–1757. doi:10.1016/0959-8049(96)00210-9 PubMedCrossRef

Moysich KB, Bonner MR, Beehler GP, Marshall JR, Menezes RJ, Baker JA, Weiss JR, Chanan-Khan A (2007) Regular analgesics use and risk of multiple myeloma. Leuk Res 31:547–551. doi:10.1016/j.leukres.2006.07.027 PubMedCrossRef

Nieters A, Kallinowski B, Brennan P, Ott M, Maynadié M, Benavente Y, Foretova L, Cocco PL, Staines A, Vornanen M, Whitby D, Boffetta P, Becker N, de Sanjosé S (2006) Hepatitis C and risk of lymphoma: results of the european multicenter case–control study EPILYMPH. Gastroenterology 131:1879–1886. doi:10.1053/j.gastro.2006.09.019 PubMedCrossRef

RC IA (1997) Epstein–Barr virus and Kaposi’s sarcoma Herpesvirus/Human Herpesvirus 8. IARC monographs on the evaluation of carcinogenic risks to humans, vol vol 70. IARC Press, Lyon

Shaffer AL, Rosenwald A, Staudt LM (2002) Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2:920–932. doi:10.1038/nri953 PubMedCrossRef

Talamini R, Montella M, Crovatto M, dal Maso L, Crispo A, Negri E, Spina M, Pinto A, Carbone A, Franceschi S (2004) Non-Hodgkin’s lymphoma and hepatitis C virus: a case–control study from northern and southern Italy. Int J Cancer 110:380–385. doi:10.1002/ijc.20137 PubMedCrossRef

Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94:252–266PubMed

Ulcickas YM, Quesenberry CB, Guo D, Caldwell G, Wells K, Shan J, Sanders L, Skovron ML, Iloeje U, Manos MM (2007) Incidence of non-Hodgkin’s lymphoma among individuals with chronic hepatitis B virus infection. Hepatology 46:107–112. doi:10.1002/hep.21642 CrossRef

Wang F, Xu R, Han B, Shi Y, Luo H, Jiang W, Lin T, Huang H, Xia Z, Guan Z (2007) High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer 109:1360–1364. doi:10.1002/cncr.22549 PubMedCrossRef

Weiss JR, Baker JA, Bare MR, Menezes RJ, Nowell S, Moysich KB (2006) Opposing effects of aspirin and acetaminophen use on risk of adult acute leukaemia. Leuk Res 30:164–169. doi:10.1016/j.leukres.2005.06.023 PubMedCrossRef

Young LS, Rickinson AB (2004) Epstein–Barr virus: 40 years on. Nat Rev Cancer 4:757–768. doi:10.1038/nrc1452 PubMedCrossRef

Titel: Medical history and risk of lymphoma: results of a European case–control study (EPILYMPH)
verfasst von: Nikolaus Becker
Joan Fortuny
Tomas Alvaro
Alexandra Nieters
Marc Maynadié
Lenka Foretova
Anthony Staines
Paul Brennan
Paolo Boffetta
Pier Luigi Cocco
Silvia de Sanjose
Publikationsdatum: 01.08.2009
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 8/2009
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-009-0551-2

Neu im Fachgebiet Onkologie

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Medical history and risk of lymphoma: results of a European case–control study (EPILYMPH)